With strategic backing from capital including Microsoft (MSFT) and SoftBank, OpenAI recently officially completed the acquisition of healthcare startup Torch for approximately $100 million. Founded last year by four employees, this company focuses on developing solutions capable of integrating multi-dimensional medical data such as lab test results, medication information, and consultation recordings. The entire Torch team will join OpenAI to jointly advance the development of its new healthcare product, ChatGPT Health.
The core objective of ChatGPT Health, recently launched by OpenAI, is to empower users to manage their own health more comprehensively, preparedly, and confidently through intelligent tools. The product features specialized encryption and isolation functions designed to protect and segregate health conversation content, ensuring that user privacy data is fully safeguarded throughout the interaction process. OpenAI emphasizes that the service is intended to complement, not replace, professional medical judgment. Currently, over 200 million people consult ChatGPT on health-related questions weekly, and to refine its functionality, the company has consulted more than 260 doctors over the past two years.
Torch was founded with the original intent of creating a “medical memory” for artificial intelligence, unifying fragmented records into a context engine to help users connect clues and see the complete picture. Upon joining OpenAI, this vision will be realized on a larger scale. OpenAI stated that deeply integrating Torch’s technology with ChatGPT Health will open new pathways for understanding and managing personal health. This move also reflects tech companies’ active targeting of the healthcare market, seeking to use artificial intelligence to analyze health data patterns and provide personalized recommendations, though it has simultaneously raised external concerns about privacy and security risks.
The application of AI in the healthcare field is continuously expanding and deepening. Recently, NVIDIA and Eli Lilly announced they will invest $1 billion over the next five years to build a joint research lab in the San Francisco Bay Area, accelerating the application of artificial intelligence in the pharmaceutical industry. NVIDIA CEO Jensen Huang believes that life sciences will be one of the fields most profoundly impacted by AI. The collaboration between the two parties will not be limited to drug discovery but will also explore opportunities for AI applications in clinical development, manufacturing, and commercial operations.
Meanwhile, industry catalysts continue to emerge. The AI healthcare industry is entering a golden period of development, with achievements such as AI-assisted medical imaging diagnosis, intelligent surgical robots, and AI platforms for drug R&D accelerating their implementation. Industrial chain collaboration is forming a complete ecosystem. With technological advancements and rising health demands, the market is expected to continue expanding. While sectors such as medical devices and innovative drugs still await policy optimization or technological breakthroughs—meaning their overall sustainability may lag behind the tech mainline—structural opportunities arising from integration with innovative technologies remain worthy of attention.
